Table 3 Incidence and risk factors of edema and/or lymphedema of lower leg after treatment of ovarian cancer
From: Lower extremity edema in patients with early ovarian cancer
First author | Year | Study design | N. of OC patients (N. of total GC patients) | Stage | Diagnostic criteria | Incidence (%) | Risk factor for LEE/LLL | Comment |
|---|---|---|---|---|---|---|---|---|
Ryan M. | 2003 | CQ & MRR | 141 (487) | NA | · Diagnosed LLL | · 7.1% (10/141) in OC | – | · MTFOTL: 3, 6, 12, and 60 months in 53, 18, 13, and 16% of the patients with GC. |
· 18.3% (89/487) in all GC | ||||||||
· 62.2% (28/45) after GLND | · Highest rate of LLL after GLND (50–62.2%). | |||||||
· 50.0% (47/233) after GLND + PLND | ||||||||
Panici PB. | 2005 | Multi-center Italian RCT | 427 | III, 406 (95.1%) | · Diagnosed LLL | · 6.5% (14/216) vs. 0% (0/211) in SL vs. LNS | · SL compared to LNS | · Improvement of SL on PFS, but not OS. |
IV, 21 (4.9%) | ||||||||
Magginoi A. | 2006 | Multi-center Italian RCT | 268 | I, 192 (72.7%) | · Diagnosed LLL | · 5.8% (8/138) vs. 0% (0/130) in SL vs. LNS | · SL compared to LNS | · No improvement of SL on PFS and OS. |
II, 72 (27.3%) | ||||||||
Beesley V. | 2007 | PRO via mail | 234 (802) | NA | · PRO - LEE | · LEE, 15.8% (37/234) | – | · Lowest incidence (4.7%) of LLL among GC |
· Diagnosed LLL | ||||||||
· LLL, 4.7% (11/234) | · BMI is not risk factor. | |||||||
Tanaka T. | 2007 | CQ & MRR | 21 (184) | I–II, 17 (81%) | · PRO - LEE | · 41.7% (5/12) in RC vs. | – | · RC is not risk factor. This should be investigated again in larger number of patients. |
III–IV, 4 (19%) | · 22.2% (2/9) in non-RC | |||||||
Tada H. | 2009 | Multi-center Japanese Retrospective | 135 (694) | I–II, 75 (55.6%) | · Diagnosed & symptomatic LLL | · 20.7% (28/135) | · RT, OR 1.79 (95%CI, 1.20-2.68) | · MTFOTL: 4.6 (0.1–40.2) months |
· LLL, 25.8 vs. 31.7% in PALND(-) vs. (+) | ||||||||
III–IV, 60 (44.4%) | ||||||||
Matsuo K. | 2011 | Retrospective | 276 | I–II, 43 (15.6%) | · MRR | · LEE, 6.5% (18/276) | – | · LEE at initial diagnosis is an important on PFS (4.9 vs. 15.3 months) and OS (5.9 and 49.1 months). |
III–IV, 233 (84.5%) | ||||||||
· LEE is the 14th symptoms. | ||||||||
Karlan BY. | 2012 | RCT | 161 | Recurrent OC | · Peripheral edema | · LEE, 51-71% vs. 22% in AMG 386* vs. Control | AMG386 administered patients | · LEE, 51 & 71% (AMG 386 3 & 10 mg/kg QW with paclitaxel QW) vs. 22% in AMG 386* vs. Control (weekly paclitaxel (80 mg/m2 QW) |
Achouri A. | 2012 | Retrospective | 36 (88) | NA | · Diagnosed LLL | · 5.6% (2/36) | · Postoperative drainage, OR 0.13 (95%CI, 0.02-0.69) | · Incidence of LLL, 11.4% and 23.5% in EC and CC. |
· BMI, surgical approach (laparoscopy and laparotomy), PALND, SPOL, number of LND is not risk factor for LLL | ||||||||
Lim MC. | 2013 Current study | CQ & MRR | 71 | I, 52 (73.3%) | · PRO - LEE | · 40.8% (29/71) | – | · MTFOTL: <1, 3, 6, and 12 months in 63,18.5, 7.4, and 3.7% |
II, 19 (26.7%) | ||||||||
· Median duration of LEE: <6, 12, 60, and ≥60 in 27.3, 9.1, 22.7, and 40.9% |